Zynex (NASDAQ:ZYXI) Stock Rating Lowered by LADENBURG THALM/SH SH

Zynex (NASDAQ:ZYXI - Get Free Report) was downgraded by research analysts at LADENBURG THALM/SH SH from a "buy" rating to a "neutral" rating in a research report issued on Wednesday, MarketBeat Ratings reports.

Separately, HC Wainwright reiterated a "buy" rating and set a $17.00 target price on shares of Zynex in a research report on Friday, December 6th.

Zynex Stock Performance

NASDAQ:ZYXI traded down $0.51 during mid-day trading on Wednesday, reaching $2.90. 1,325,854 shares of the stock were exchanged, compared to its average volume of 132,488. The stock has a market capitalization of $92.35 million, a P/E ratio of 19.33 and a beta of 0.81. Zynex has a 1 year low of $2.78 and a 1 year high of $13.19. The company has a 50 day simple moving average of $7.52 and a 200-day simple moving average of $7.95. The company has a quick ratio of 3.15, a current ratio of 3.94 and a debt-to-equity ratio of 1.66.

Zynex (NASDAQ:ZYXI - Get Free Report) last posted its quarterly earnings data on Tuesday, March 11th. The company reported ($0.02) EPS for the quarter, missing analysts' consensus estimates of $0.09 by ($0.11). Zynex had a net margin of 2.49% and a return on equity of 13.05%. The business had revenue of $45.98 million during the quarter, compared to analyst estimates of $53.65 million. During the same quarter in the prior year, the firm posted $0.04 earnings per share. Analysts anticipate that Zynex will post 0.2 earnings per share for the current fiscal year.

Remove Ads

Insider Activity

In related news, CFO Daniel J. Moorhead sold 10,000 shares of the stock in a transaction on Monday, February 3rd. The stock was sold at an average price of $7.68, for a total transaction of $76,800.00. Following the sale, the chief financial officer now owns 19,738 shares of the company's stock, valued at $151,587.84. This trade represents a 33.63 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Insiders have sold 30,000 shares of company stock worth $227,100 over the last ninety days. 52.13% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the company. Hotchkis & Wiley Capital Management LLC lifted its position in Zynex by 24.7% during the third quarter. Hotchkis & Wiley Capital Management LLC now owns 746,380 shares of the company's stock worth $6,090,000 after buying an additional 147,770 shares during the period. Geode Capital Management LLC increased its stake in shares of Zynex by 4.1% during the 4th quarter. Geode Capital Management LLC now owns 443,020 shares of the company's stock valued at $3,549,000 after acquiring an additional 17,511 shares during the last quarter. Royce & Associates LP boosted its position in shares of Zynex by 9.2% in the third quarter. Royce & Associates LP now owns 257,291 shares of the company's stock worth $2,099,000 after acquiring an additional 21,781 shares during the last quarter. Janney Montgomery Scott LLC grew its holdings in Zynex by 10.3% in the fourth quarter. Janney Montgomery Scott LLC now owns 159,259 shares of the company's stock valued at $1,276,000 after purchasing an additional 14,820 shares during the period. Finally, Renaissance Technologies LLC grew its holdings in Zynex by 2.8% in the fourth quarter. Renaissance Technologies LLC now owns 137,362 shares of the company's stock valued at $1,100,000 after purchasing an additional 3,800 shares during the period. 29.68% of the stock is currently owned by hedge funds and other institutional investors.

Zynex Company Profile

Zynex, Inc, together with its subsidiaries, designs, manufactures, and markets medical devices to treat chronic and acute pain; and activate and exercise muscles for rehabilitative purposes with electrical stimulation. The company offers NexWave, a dual channel, multi-modality interferential current, transcutaneous electrical nerve stimulation, and neuromuscular electrical stimulation (NMES) device that is marketed to physicians and therapists by field sales representatives; NeuroMove, an electromyography and electric stimulation technology device; InWave, an electrical stimulation product for the treatment of female urinary incontinence; E-Wave, an NMES device; M-Wave, an NMES device.